title: Motor complications in Parkinson disease: a prospective follow-up study.
abstract: Currently, Parkinson disease (PD) can be symptomatically controlled with standard treatments; however, after a few years this response typically declines. The authors carried out a prospective practice-based study to evaluate the evolution and motor complications during the first 5 years in 59 de novo PD patients. They observed a significant improvement in UPDRS scores during the first year, then the UPDRS mean score declined progressively, especially after the third year (UPDRS score at baseline, 27 points; year 1, 19 points; year 2, 20.3 points; year 3, 22.6 points; year 4, 24.9 points; year 5, 29.5 points). Motor fluctuations, dyskinesias, and freezing also increased after year 3 from 10%, 16%, and 8% respectively to 35%, 32%, and 27% at year 5. At 5 years, 50% of patients (30 of 59) still had UPDRS scores better or equal to baseline, and 44% (26 of 59) had no motor complications. This latter group represented 38% of those subjects initially treated with levodopa and 52% initially treated with other agents.
authors.affiliation: Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain. pgarcia@fjd.es
authors.forename: Pedrox J
authors.initials: PJ
authors.lastname: García Ruiz
authors.forename: Elena
authors.initials: E
authors.lastname: Meseguer
authors.forename: Javier
authors.initials: J
authors.lastname: Del Val
authors.forename: Ana
authors.initials: A
authors.lastname: Vázquez
authors.forename: Vicenta
authors.initials: V
authors.lastname: Sanchez Bernardos
authors.forename: Antonio
authors.initials: A
authors.lastname: Vázquez
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D020820:Dyskinesias / Q000209:etiology / Q000503:physiopathology*; D005500:Follow-Up Studies; D005684:Gait / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa